Professional Documents
Culture Documents
Achalasia
Achalasia
Defective
Neurodegenerative
LES
Incidence 1.63/100.000
PATHOGENESIS
Autoimmune
Inflamatory process
Inhibit NO
SYMPTOMPS
Dysphagia Heart burn
Mechanical
or
Rule Out Endoscopy
Anatomic
Obstruction
DIAGNOSTIC APPROACH
Barium-swallow
Complementary test
Esophageal Dilation
And
Tapered Distal Esophagus
RECENT ADVANCES IN THE DIAGNOSIS OF DYSPHAGIA
: HIGH-RESOLUTION MANOMETRY (HRM)
• MECHANICAL
EXCLUDED • ANATOMICAL
• ACHALASIA
HRM : • EGJ OUTFLOW OBSTRUCTION
• OTHER MAJOR PERISTALTIC
GOLD STANDARD
DISORDERS
RECENT ADVANCES IN THE DIAGNOSIS OF DYSPHAGIA
: HIGH-RESOLUTION MANOMETRY (HRM)
TREATMENT OUTCOMES BEING BEST IN TYPE II, INTERMEDIATE FOR TYPE I, AND WORST IN TYPE III .
TREATMENT
IRREVERSIBLE
ACHALASIA
OPTIONS DISEASE
ENDOSCOPY
SURGICAL
(PNEUMATIC
(LHM)
DILATATION OR POEM)
TREATMENT
OPTIONS Muscle Relaxant DISADVANTAGES
• Nitric Oxide • Limited efficacy
PHARMACOLOGICAL • Calcium Channel • Temporary effect
AGENTS Blockers • ADVERSE
• Sildenafil EVENTS :
headache,
edema, and
dizziness
TREATMENT
OPTIONS MAIN EFFECT MAIN LIMITATION
In most centers :
performed in two treatments with 30 mm and 35 mm
balloon dilatations performed 2 to 4 weeks apart.
TREATMENT
MAIN
OPTIONS PROCEDURE
COMPLICATION
Creating a MYOTOMY
SUBMUCOSAL TUNNEL Passing through the
accessed through a tunnel into the of the circular muscles
mucosal orifice within the mainly with an
EGJ REGION
esophageal wall endoscopic knife
NOVEL ADVANCES IN THERAPY : POEM
Hydrothorax
Meta-analysis Study in 2015 by Barbieri et al :
551 patients showing a pooled success rate of 93%,
though the follow-up period was very diverse (from 3
Late Bleeding
months - 3 years)
Major
adverse events
Retrospective study of 1680 chinese patients : Pneumothorax
major adverse events rate is 3.3%
ICU Admission
NOVEL ADVANCES IN THERAPY : POEM
POEM vs Baloon Indications
dilation vs LHM other than Achalasia